Blog

Cardiometabolic Research Advances Using GLP-1 Receptor Therapy

Find out about GLP-1 receptor therapy on cardiometabolic health and its revolutionary role in modern medicine and patient care.

Abstract

Hello, I’m Dr. Alex Jimenez, and I am honored to share transformative insights into managing cardiovascular and metabolic conditions, such as type 2 diabetes. This educational post explores a significant shift in our medical understanding, moving from a purely glucose-centric model to a comprehensive, risk-reduction strategy. Here, we will journey through the latest findings from leading researchers, backed by robust, evidence-based studies, to understand this new paradigm. We’ll delve into the mechanisms of two groundbreaking classes of medications—SGLT2 inhibitors and GLP-1 receptor agonists—and their profound benefits for cardiovascular and renal health, often independent of their glucose-lowering effects. We will also discuss how our multidisciplinary team at Injury Medical Clinic PA, including the invaluable medical direction of Dr. Maria Guadalupe Cardenas, MD, integrates these advancements with integrative chiropractic care, functional medicine, and rehabilitation to provide a truly holistic treatment plan for our patients in El Paso, Texas. This post aims to illuminate the interconnectedness of cardiac, metabolic, and kidney health and present a collaborative path forward for optimal patient outcomes.

Our Collaborative and Integrative Practice at Injury Medical Clinic PA

Before we delve into the clinical science, I want to take a moment to explain our unique approach to patient care here in El Paso, Texas. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, we have built a truly multidisciplinary practice. I am Dr. Alex Jimenez, and my credentials include DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST. My passion lies in functional medicine and chiropractic care, focusing on the body’s innate ability to heal and the musculoskeletal system’s foundational role in overall health.
A cornerstone of this model is my collaboration with Dr. Maria Guadalupe Cardenas, MD. With over 40 years of experience as a board-certified internist, Dr. Cardenas serves as our Medical Director and Collaborative Physician (NPI #1164426749, Texas MD License #J2933). Her extensive expertise in internal medicine provides essential medical oversight and direction, allowing us to seamlessly merge advanced medical protocols with chiropractic, functional medicine, rehabilitation, and personal injury care.
Our model is built on the synergy between different disciplines:

• Medical Oversight (Dr. Cardenas): Provides diagnoses, prescribes medications like the advanced therapies we will discuss today, and oversees the overall medical treatment plan, ensuring patient safety and efficacy.
• Chiropractic and Functional Medicine (Dr. Jimenez): I focus on identifying and addressing the root causes of dysfunction. Through chiropractic adjustments, we restore proper nerve function and biomechanics. With functional medicine, we analyze a patient’s genetics, lifestyle, and environment to correct underlying imbalances in metabolism, inflammation, and gut health.
• Integrated Services: Together, we manage personal injury cases, rehabilitation, nutritional counseling, and chronic disease management. This team-based approach ensures that a patient with diabetes, for example, not only receives the latest medications but also benefits from dietary overhauls, targeted supplementation, and structural care to improve insulin sensitivity and reduce systemic inflammation. This is the essence of integrative medicine—uniting the best of multiple worlds for superior patient outcomes.

The Critical Link Between Diabetes and Cardiovascular Disease

For a long time, the primary focus in managing type 2 diabetes was on lowering blood glucose. While important, this approach was incomplete. We now have an overwhelming body of evidence showing that people with diabetes face a significantly elevated risk for Atherosclerotic Cardiovascular Disease (ASCVD), which includes coronary heart disease, stroke, and peripheral arterial disease. In fact, ASCVD is the leading cause of death for individuals with diabetes.

• Consider this startling fact: over 70% of individuals with diabetes over the age of 65 will likely succumb to heart disease or a stroke.
• Following a heart attack (myocardial infarction or MI), people with diabetes have a much higher mortality risk and a poorer long-term prognosis.
• These grim outcomes persist even when blood sugar levels are well-controlled, and they affect individuals with both type 1 and type 2 diabetes.

This reality has forced a paradigm shift in how we manage these interconnected conditions. The focus has expanded from aggressive glucose reduction to a holistic strategy to reduce overall cardiovascular and renal risk. This involves managing not just blood sugar, but also blood pressure, cholesterol levels, weight, physical activity, and smoking cessation. For the first time in my career, all the major guideline-issuing bodies—including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease: Improving Global Outcomes (KDIGO)—are in complete agreement on this new, integrated approach to care. This consensus marks a monumental step forward, allowing us to view and treat our patients through a unified, comprehensive lens.

Rethinking Treatment Algorithms: A Risk-Based Approach

This new paradigm is reflected in the latest treatment algorithms from the American Diabetes Association. The guidelines now emphasize a risk-stratified approach. For any patient with type 2 diabetes who has established ASCVD, heart failure, chronic kidney disease (CKD), or is at high risk for developing these conditions, the recommendation is to concurrently address all risk factors and prioritize specific classes of medications.
The algorithm directs us to move beyond traditional first-line agents like metformin alone and immediately consider two powerful classes of drugs:

1. SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors
2. GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists

These medications are now recommended as foundational therapies for high-risk patients precisely because they have demonstrated proven cardiovascular (CV) benefits in large-scale clinical trials. The choice between them, or the decision to use them in combination, depends on patient-specific factors, comorbidities, and preferences. This marks a significant departure from simply trying to lower the A1C; it’s about proactively protecting the heart and kidneys.

The History and Evolution of Diabetes Medication Trials

How did we arrive at this pivotal moment? The story begins around 2008, when the U.S. Food and Drug Administration (FDA) issued mandatory guidance for all new antidiabetic medications. The FDA required pharmaceutical companies to conduct long-term Cardiovascular Outcomes Trials (CVOTs). The primary goal was to ensure that these new drugs did not increase the risk of Major Adverse Cardiovascular Events (MACE)—a composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death.
This mandate was a direct response to past experiences where certain drugs, such as rosiglitazone (Avandia) and others like Vioxx, were later found to cause cardiovascular harm. Earlier studies were often too short, underpowered, or poorly designed to detect these risks. The FDA’s new requirement forced the industry to conduct large, well-designed, placebo-controlled trials that were robust enough to demonstrate safety or non-inferiority.
What happened next was truly surprising. As the results of these CVOTs began to be published, starting with the EMPA-REG OUTCOME trial for empagliflozin (Jardiance) in 2015, researchers discovered something extraordinary. These new drugs weren’t just safe—some of them were actively protective.

• Empagliflozin (Jardiance), an SGLT2 inhibitor, was the first to show a significant reduction in MACE, CV death, and hospitalization for heart failure.
• Liraglutide (Victoza), a GLP-1 receptor agonist, followed in 2016 with the LEADER trial, also demonstrating significant cardiovascular benefits.

These unexpected findings of superiority, not just safety, were game-changers. They provided the evidence needed to completely overhaul the clinical guidelines and place these drug classes at the forefront of managing patients with cardiovascular, metabolic, and renal disease.

A Deeper Dive into SGLT2 Inhibitors

Let’s explore the SGLT2 inhibitor class more closely. These medications work by blocking glucose reabsorption in the kidney, causing excess sugar to be excreted in the urine. While this helps lower blood glucose, their profound cardiovascular and renal benefits appear to stem from multiple other mechanisms.

Landmark Cardiovascular Outcomes Trials for SGLT2 Inhibitors

Several major CVOTs have established the benefits of this class:

• EMPA-REG OUTCOME (empagliflozin/Jardiance): This trial was a watershed moment. It showed a highly statistically significant reduction in MACE, CV death, and hospitalization for heart failure.
• CANVAS Program (canagliflozin/Invokana): Demonstrated significant reductions in MACE and hospitalization for heart failure.
• DECLARE-TIMI 58 (dapagliflozin/Farxiga): While it didn’t show a significant reduction in MACE, it showed a substantial and statistically significant reduction in the risk of hospitalization for heart failure.
• VERTIS-CV (ertugliflozin/Steglatro): Also showed a significant reduction in hospitalization for heart failure risk (a 30% relative risk reduction).

The consistent and powerful effect on reducing hospitalizations for heart failure across the class is particularly noteworthy and has led to their widespread adoption in cardiology.

The Multifaceted Mechanisms of SGLT2 Inhibitors

What makes these drugs so effective? The benefits go far beyond simple glucose lowering. Some of the proposed mechanisms that contribute to their cardioprotective and renoprotective effects:

• Hemodynamic Effects: SGLT2 inhibitors have a mild diuretic effect, which helps reduce blood pressure by about 3-5 mmHg systolic. This is achieved through natriuresis, or the excretion of sodium and water, which reduces fluid volume and preload on the heart.
• Reduced Glomerular Pressure: In the kidneys, these drugs reduce pressure within the glomerulus (the kidney’s filtering unit). This is a key theorized mechanism for their nephroprotective (kidney-protecting) effects, slowing the progression of diabetic kidney disease.
• Metabolic Shifts: SGLT2 inhibitors promote a slight shift towards ketosis. The heart is a unique metabolic organ that can efficiently use ketones as a fuel source. This “super fuel” improves myocardial efficiency and function, especially in a stressed or failing heart.
• Systemic Benefits: They also contribute to a modest weight loss (around 5-7 pounds), reduce inflammation, decrease oxidative stress, and may improve endothelial function and stabilize atherosclerotic plaques.
• Improved Myocardial Energetics: By reducing the workload on the heart (via lower blood pressure and volume) and providing a more efficient fuel source (ketones), these drugs improve the overall energy balance and function of the heart muscle.

SGLT2 Inhibitors in Heart Failure and Kidney Disease

The benefits of SGLT2 inhibitors have been so profound that their use has expanded to patients without diabetes.

Heart Failure Trials

• DAPA-HF and EMPEROR-Reduced: These trials studied dapagliflozin and empagliflozin, respectively, in patients with heart failure with reduced ejection fraction (HFrEF). Both showed a remarkable 25-26% relative risk reduction in the composite outcome of cardiovascular death or hospitalization for heart failure, regardless of whether the patients had diabetes.
• EMPEROR-Preserved: This was the first trial to show a meaningful benefit in patients with heart failure with preserved ejection fraction (HFpEF), a very common and difficult-to-treat type of heart failure, particularly in older adults, women, and those with obesity. Empagliflozin reduced the primary composite endpoint by 21%.

Kidney Disease Trials

The evidence for kidney protection is just as compelling:

• DAPA-CKD (dapagliflozin): This trial was stopped early due to overwhelming efficacy. It showed a 39% reduction in the risk of progression of kidney disease.
• EMPA-KIDNEY (empagliflozin): Also demonstrated a significant 28% reduction in the risk of kidney disease progression or cardiovascular death.
• CREDENCE (canagliflozin): Showcased a 30% reduction in the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and kidney disease.

These trials have firmly established SGLT2 inhibitors as a cornerstone therapy for chronic kidney disease, even in patients without diabetes.

Understanding the Incretin Effect: TheBody’ss Natural Glucose Response System

For years, the management of type 2 diabetes centered on a few key strategies. However, a fascinating discovery completely shifted our understanding and opened the door to a new class of powerful therapies. Researchers observed a peculiar phenomenon: when people consumed glucose orally (by drinking it), their bodies produced a much more robust insulin response to lower blood sugar than when the same amount of glucose was administered intravenously (IV). This observation led them to a logical conclusion: there must be something happening in the gut when food is ingested that signals the pancreas to ramp up insulin production.
This phenomenon was termed the “incretin effect.” The “somethings” responsible were identified as gut hormones called incretins, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

• The Process: When you eat, food travels to your stomach and intestines. Specialized cells in your gut (L-cells) detect the presence of nutrients and release GLP-1 and GIP into your bloodstream.
• The Signal: These hormones then travel to the pancreas, where they act as messengers. They bind to receptors on pancreatic beta cells, stimulating the cells to release insulin.
• The Result: This insulin release helps your body’s cells take up glucose, effectively lowering your blood sugar levels after a meal.

Crucially, this entire process is glucose-dependent. This means the incretins only stimulate insulin release when blood sugar levels are high, as they are after a meal. This built-in safety mechanism significantly reduces the risk of hypoglycemia (dangerously low blood sugar) when these pathways are targeted with medication, especially compared to older diabetes drugs.

The Blunted Incretin Effect in Type 2 Diabetes

One of the key physiological defects we see in patients with type 2 diabetes is a blunted or even absent incretin effect. Their bodies produce insufficient amounts of native GLP-1 in response to food. This deficiency contributes significantly to the hallmarks of the disease:

• Poor Post-Meal Glucose Control: Without a strong incretin signal, the pancreas doesn’t release sufficient insulin after eating, resulting in prolonged periods of high blood sugar.
• Dysregulated Appetite: Native GLP-1 also plays a critical role in promoting satiety, or the feeling of fullness. Low levels of this hormone can lead to a state of poor satiety, contributing to overeating and the obesity that is so often a comorbid condition with type 2 diabetes.
• Excess Glucagon Secretion: GLP-1 normally helps suppress the release of another hormone called glucagon. Glucagon tells the liver to produce and release more sugar into the bloodstream (gluconeogenesis). In type 2 diabetes, this suppression is impaired, so the liver continues to release glucose even when blood glucose is already high.

Understanding this hormonal defect was the key that unlocked the development of GLP-1 receptor agonists—medications designed to mimic the action of our natural GLP-1 and restore these vital functions.

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

How GLP-1 Receptor Agonists Revolutionize Treatment

GLP-1 receptor agonists are a class of medications that bind to and activate GLP-1 receptors throughout the body, just as our native GLP-1 would, but they are engineered to last much longer. Their multifaceted mechanism of action addresses several core issues in type 2 diabetes and obesity simultaneously.

• Stimulates Insulin Secretion: By activating pancreatic receptors, they prompt a glucose-dependent release of insulin, directly lowering blood sugar.
• Inhibits Glucagon Secretion: They effectively tell the liver to stop producing excess sugar, which is a major contributor to high fasting and post-meal glucose levels.
• Slows Gastric Emptying: This is a key mechanism for both glucose control and weight loss. By slowing down the rate at which food leaves the stomach, they prevent rapid spikes in blood sugar after meals. This delay also contributes to a prolonged feeling of fullness, which naturally leads to a decrease in overall food intake. This effect is often responsible for the common initial side effects like nausea, but it is also a primary driver of the medication’s success.
• Increases Satiety: GLP-1 receptor agonists act directly on appetite centers in the brain, enhancing the feeling of fullness and reducing food cravings. This neurobiological effect is fundamental to the significant weight loss seen with these therapies.

Collectively, these actions lead to profound improvements in A1c, blood glucose, and body weight, tackling the metabolic dysfunction of type 2 diabetes at its source.

The Challenge of Over-Basalization: A Case Study

To truly understand the paradigm shift in diabetes care,let’ss consider a typical patient I might see in our clinic, whom we’ll call Tony. He represents a common challenge where adding a GLP-1 agonist is the superior strategy.

• Patient Profile: Tony
• Age: 62 years
• Diagnosis: Type 2 Diabetes (11 years), Hyperlipidemia, Hypertension
• Recent A1c: 8.2% (well above the target of <7.0%)
• Kidney Health: Proteinuria (protein in the urine), an early sign of kidney damage.
• Current Medications:
  • Degludec (basal insulin): 65 units daily
  • Metformin: 1000 mg twice daily
  • An SGLT2 inhibitor daily
  • A statin for cholesterol
• An ARB for blood pressure
• Physical Stats: Weight 220 lbs, Height 5’9 ” “, BMI 32.5 (classifies as obese)
• Blood Sugar Patterns:
  • Fasting Glucose (morning): 15050 mg/dL
  • Postprandial Glucose (after meals/bedtime): 160-200 mg/dL

Tony’s case highlights a critical issue we call over-basalization. We’ve pushed his basal (long-acting) insulin dose to a high level, yet his A1c and post-meal sugars remain dangerously elevated. Research in pharmacokinetics reveals that once you exceed a certain dose of basal insulin, typically around 0.5 units per kilogram of body weight per day, you get diminishing returns. For Tony, who weighs 100 kg (220 lbs), this threshold is about 50 units. He is already on 65 units, pushing him past the point of modest glycemic effect and into the territory of significant side effects, primarily weight gain and a higher risk of hypoglycemia.
For a patient like Tony, the conventional next step might have been to add prandial (mealtime) insulin. While this can control post-meal spikes, it comes with a heavy price: a near-certainty of further weight gain and a significantly increased risk of hypoglycemia. Given his BMI of 32.5, adding more weight would only worsen his insulin resistance, creating a vicious cycle.
This is where the 2024 guidelines from the American Diabetes Association (ADA) strongly recommend adding a GLP-1 receptor agonist. It addresses multiple problems at once, moving beyond simple glucose lowering, weight loss, and cardiovascular protection, which are crucial for a high-risk patient like Tony.

Beyond Blood Sugar: The Cardiovascular and Renal Benefits of GLP-1s

Perhaps the most exciting development in the story of GLP-1 agonists is the overwhelming evidence of their protective effects on the heart and kidneys. Several landmark trials have established these powerful benefits:

• The LEADER Trial (Liraglutide): This trial studied patients with type 2 diabetes and high cardiovascular risk. It showed a significant reduction in the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, and non-fatal stroke.
• The SUSTAIN-6 and PIONEER 6 Trials (Semaglutide): Both the injectable (SUSTAIN-6) and oral (PIONEER 6) forms of semaglutide were studied in patients with high cardiovascular risk. Both trials demonstrated a robust reduction in MACE, confirming the class effect.
• The REWIND Trial (Dulaglutide): What made this trial unique was its focus on a broader population, including many patients who had risk factors for cardiovascular disease but had not yet had an event. It demonstrated that dulaglutide can be used for primary prevention, reducing the risk of a first cardiovascular event.
• Tirzepatide (Mounjaro®, Zepbound™): This is a newer, highly potent dual GIP/GLP-1 receptor agonist. While its final CVOTs are still pending as of June 15, 2026, preliminary data suggest powerful cardiovascular benefits are likely.

More recently, the FLOW trial for semaglutide was stopped early because of overwhelmingly positive results showing a significant reduction in the risk of kidney disease progression (nephropathy). These findings are game-changers, solidifying the role of GLP-1 agonists as essential therapies for patients with or at high risk for heart and kidney disease.

Navigating Side Effects and Safety Considerations of GLP-1 Agonists

As with any potent medication, GLP-1 agonists are not without side effects. As clinicians, our job is to help patients navigate these challenges.

• Gastrointestinal (GI) Issues: Nausea, vomiting, and diarrhea are common and caused by delayed gastric emptying. My clinical advice is always to “start low and go slow,” beginning with the lowest dose and titrating upwards gradually.
• Dehydration and Acute Kidney Injury (AKI): Patients on these medications must drink plenty of water to prevent dehydration due to GI side effects.
• Gallbladder Disease: Rapid weight loss, regardless of the method, is associated with an increased risk of gallstone formation.
• Pancreatitis: Recent large-scale studies as of early 2025 have been reassuring, finding no statistically significant increase in the risk of pancreatitis and even suggesting a potential long-term risk reduction by improving metabolic health.
• Thyroid C-Cell Tumors: These medications carry a black box warning due to an increased risk of thyroid C-cell tumors in rodents. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Muscle and Bone Loss: This is a feature of significant weight loss in general, not something specific to these drugs. This is where our integrative care becomes critical.

An Integrative Chiropractic Perspective on Metabolic Health

As a Doctor of Chiropractic with advanced training in functional medicine, I view the body as an integrated system. When I see a patient, I don’t just see a person with diabetes and heart disease. I see a complex interplay of systemic inflammation, metabolic dysfunction, and biomechanical stress. This is where our unique approach at Injury Medical Clinic PA provides immense value. The side effects and physiological changes associated with modern diabetes therapies are whole-body issues we can address.
Here’s how integrative chiropractic care fits into this new paradigm:

1. Addressing Systemic Inflammation: Chronic inflammation is a root cause of both ASCVD and insulin resistance. Chiropractic adjustments have been shown to modulate the nervous system and can have a downstream effect on inflammatory pathways. By reducing spinal misalignments (subluxations), we can help normalize nerve function, which in turn influences the body’s inflammatory response.
2. Promoting Physical Activity and Combating Muscle Loss: Exercise is a critical component of managing diabetes. However, many patients are limited by musculoskeletal pain. As chiropractors, our primary role is to improve biomechanical function, reduce pain, and restore mobility. Furthermore, with the rapid weight loss induced by GLP-1s, there is a risk of sarcopenia (muscle loss). We implement targeted strength training and rehabilitation protocols to preserve and build lean muscle mass. By treating underlying musculoskeletal issues, we empower patients to engage in the physical activity necessary for their metabolic health.
3. Functional Medicine and Nutritional Counseling: My training as a Certified Functional Medicine Practitioner (CFMP) allows us to go deeper. We create personalized nutrition plans and recommend targeted supplementation to reduce inflammation, improve insulin sensitivity, and support cardiovascular health. To combat muscle loss, we ensure patients consume adequate protein to support muscle synthesis. This complements the work of medications by addressing the foundational lifestyle factors that drive disease.
4. Stress Management and Autonomic Balance: The autonomic nervous system plays a huge role in regulating blood pressure, heart rate, and metabolic function. Chronic stress leads to a state of sympathetic (“fight-or-flight”) dominance, which can worsen hypertension and insulin resistance. Chiropractic care, along with techniques like breathwork and meditation, helps promote a parasympathetic (“rest-and-digest”) state, supporting better cardiovascular and metabolic regulation.

In our clinic, a patient would receive a comprehensive plan. Under the medical direction of Dr. Cardenas, they might be started on an SGLT2 inhibitor or a GLP-1 agonist. Simultaneously, my team would work with them on a personalized plan including chiropractic adjustments to improve mobility, an anti-inflammatory diet, and a progressive exercise program they can perform without pain. This integrated approach addresses the disease from multiple angles, leading to far better and more sustainable outcomes. This is the future of chronic disease management—a holistic, patient-centered, and team-based model of care.

References

• American Diabetes Association Professional Practice Committee. (2023). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2023. Diabetes Care, 46(Suppl 1), S140–S157.
• American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178.
• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H.-P., Choi, D.-J., Chordà, J., Chuquiure-Valenzuela, E., … & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., Conget, I., … REWIND Investigators. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. The Lancet, 394(10193), 121–130.
• Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., … & PIONEER 6 Investigators. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 381(9), 841-851.
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Vilsbøll, T., Hansen, O., & Buse, J. B. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., & LEADER Steering Committee. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., … & DeMets, D. L. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
• Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644–657.
• [Perreault, L., & Bain, S. (2023). Glucagon-like peptide 1 receptor agonists in the treatment of type 2 diabetes mellitus. In UpToDate. Retrieved from https://www.uptodate.com](https://www.uptodate.com)
• The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117-127.
• Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., … & Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347–357.
• Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., … & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128.

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular disease, type 2 diabetes, chronic kidney disease, heart failure, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso, TX, ASCVD, risk reduction, metabolic health, incretin effect, over-basalization, tirzepatide, semaglutide, Mounjaro, Ozempic, diabetes management, A1c reduction, weight loss and diabetes, nephroprotection, cardioprotection, collaborative care, internal medicine, chiropractic, personal injury care, musculoskeletal health